13TSB SynBio Use of Synthetic Biology methods to enhance and optimise production of a novel antibiotic

13TSB SynBio 利用合成生物学方法增强和优化新型抗生素的生产

• 批准号: BB/L004348/1
• 负责人: Mervyn Bibb
• 金额: $ 21.89万
• 依托单位: John Innes Centre
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FL004348%2F1
• 关键词: 13TSB; SynBio; Use; Synthetic; Biology

Demuris has a pipeline of novel antibiotics produced by a variety of different actinobacteria. The leading molecule is presently made by an organism that is not ideal for large scale fermentation, and the compound structure may not yet be optimal in terms of pharmacological properties. We wish to identify the antibiotic producer gene cluster and re-engineer it for production in an optimized chassis for production of actinobacterial natural products based on Streptomyces venezuelae (Sven). Pathway engineering will be used to generate analogues of the lead antibiotic, which will be used to facilitate drug optimization and IP protection

Demuris拥有一系列由各种不同放线菌生产的新型抗生素。先导分子目前由对于大规模发酵不理想的生物体制成，并且化合物结构在药理学性质方面可能还不是最佳的。我们希望确定抗生素生产基因簇，并重新设计它的生产在一个优化的底盘生产放线菌天然产物的基础上委内瑞拉链霉菌（斯文）。途径工程将用于产生先导抗生素的类似物，这将用于促进药物优化和知识产权保护